MCID: CHR020
MIFTS: 43

Chronic Interstitial Cystitis

Categories: Rare diseases, Nephrological diseases

Aliases & Classifications for Chronic Interstitial Cystitis

MalaCards integrated aliases for Chronic Interstitial Cystitis:

Name: Chronic Interstitial Cystitis 12 15 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1678
ICD10 33 N30.1
ICD9CM 35 595.1
MeSH 44 D018856
UMLS 73 C0600040

Summaries for Chronic Interstitial Cystitis

MalaCards based summary : Chronic Interstitial Cystitis is related to interstitial cystitis and cystitis. An important gene associated with Chronic Interstitial Cystitis is CDSN (Corneodesmosin), and among its related pathways/superpathways is Primary immunodeficiency. The drugs Acetylcholine and Dexmedetomidine have been mentioned in the context of this disorder. Affiliated tissues include prostate, t cells and brain.

Related Diseases for Chronic Interstitial Cystitis

Diseases in the Interstitial Cystitis family:

Chronic Interstitial Cystitis

Diseases related to Chronic Interstitial Cystitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 189)
# Related Disease Score Top Affiliating Genes
1 interstitial cystitis 11.6
2 cystitis 10.5
3 mononeuritis multiplex 10.4 CD40LG CDSN
4 mononeuritis of upper limb and mononeuritis multiplex 10.4 CD40LG CDSN
5 mononeuropathy 10.3 CD40LG CDSN
6 toxocariasis 10.2 CD40LG RNASE3
7 vasomotor rhinitis 10.2 CD40LG RNASE3
8 ancylostomiasis 10.2 CD40LG RNASE3
9 neuroretinitis 10.1 CD40LG RNASE3
10 churg-strauss syndrome 10.1 CD40LG RNASE3
11 leukocyte disease 10.1 CD40LG RNASE3
12 selective igg deficiency disease 10.0 CD40LG CD79A
13 c1q nephropathy 10.0 CD40LG CD79A
14 meningovascular neurosyphilis 10.0 CD40LG CD79A
15 alpha chain disease 10.0 CD40LG CD79A
16 brill-zinsser disease 10.0 CD40LG CD79A
17 exudative glomerulonephritis 10.0 CD40LG CD79A
18 cork-handlers' disease 10.0 CD40LG CD79A
19 salpingo-oophoritis 10.0 CD40LG CD79A
20 early yaws 10.0 CD40LG CD79A
21 systemic lupus erythematosus 10.0
22 lupus erythematosus 10.0
23 ventilation pneumonitis 10.0 CD40LG CD79A
24 axillary adenitis 10.0 CD40LG CD79A
25 cryofibrinogenemia 10.0 CD40LG CD79A
26 trichostrongyloidiasis 10.0 CD40LG CD79A
27 subacute bacterial endocarditis 10.0 CD40LG CD79A
28 heterophyiasis 10.0 CD40LG CD79A
29 immunoglobulin g deficiency 10.0 CD40LG CD79A
30 orbital granuloma 10.0 CD40LG CD79A
31 transient hypogammaglobulinemia of infancy 10.0 CD40LG CD79A
32 hyperglobulinemic purpura 10.0 CD40LG CD79A
33 gastroduodenitis 10.0 CD40LG CD79A
34 bacterial conjunctivitis 10.0 CD40LG CD79A
35 heavy chain disease 10.0 CD40LG CD79A
36 ophthalmia neonatorum 10.0 CD40LG CD79A
37 immunoglobulin a deficiency 1 10.0 CD40LG CD79A
38 cerebral arteritis 10.0 CD40LG CD79A
39 selective immunoglobulin deficiency disease 10.0 CD40LG CD79A
40 geniculate herpes zoster 10.0 CD40LG CD79A
41 erythema elevatum diutinum 10.0 CD40LG CD79A
42 sporotrichosis 10.0 CD40LG CD79A
43 fallopian tube disease 10.0 CD40LG CD79A
44 hyperimmunoglobulin syndrome 10.0 CD40LG CD79A
45 congenital syphilis 10.0 CD40LG CD79A
46 polyclonal hypergammaglobulinemia 10.0 CD40LG CD79A
47 monoclonal paraproteinemia 10.0 CD40LG CD79A
48 salpingitis 10.0 CD40LG CD79A
49 ocular toxoplasmosis 10.0 CD40LG CD79A
50 dysgammaglobulinemia 10.0 CD40LG CD79A

Graphical network of the top 20 diseases related to Chronic Interstitial Cystitis:



Diseases related to Chronic Interstitial Cystitis

Symptoms & Phenotypes for Chronic Interstitial Cystitis

Drugs & Therapeutics for Chronic Interstitial Cystitis

Drugs for Chronic Interstitial Cystitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 163)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acetylcholine Approved Phase 4,Phase 2,Phase 1 51-84-3 187
2
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
3
Oxytocin Approved, Vet_approved Phase 4 50-56-6 439302 53477758
4
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
5
Morphine Approved, Investigational Phase 4 57-27-2 5288826
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Cycloserine Approved Phase 4 68-41-7 401 6234
8
Metoprolol Approved, Investigational Phase 4 37350-58-6, 51384-51-1 4171
9
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
10
gamma-Aminobutyric acid Approved, Investigational Phase 4 56-12-2 119
11
Belladonna Approved, Experimental, Nutraceutical Phase 4
12
Citric Acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
13 abobotulinumtoxinA Phase 4,Phase 2,Phase 1
14 Botulinum Toxins Phase 4,Phase 2,Phase 1
15 Botulinum Toxins, Type A Phase 4,Phase 2,Phase 1
16 Cholinergic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Neuromuscular Agents Phase 4,Phase 2,Phase 1
18 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 onabotulinumtoxinA Phase 4,Phase 2,Phase 1
20 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
21 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable
22 Anti-Arrhythmia Agents Phase 4,Phase 2,Not Applicable
23 Adrenergic Agents Phase 4,Phase 3
24 Adrenergic Agonists Phase 4,Phase 3
25 Adrenergic alpha-2 Receptor Agonists Phase 4
26 Adrenergic alpha-Agonists Phase 4
27 Analgesics Phase 4,Phase 3,Phase 2
28 Analgesics, Non-Narcotic Phase 4,Phase 3
29 Anti-Anxiety Agents Phase 4
30 Hypnotics and Sedatives Phase 4,Not Applicable
31 Oxytocics Phase 4
32 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
33 Anti-Inflammatory Agents, Non-Steroidal Phase 4
34 Antirheumatic Agents Phase 4,Phase 3,Phase 2
35 Cyclooxygenase Inhibitors Phase 4
36 Ketorolac Tromethamine Phase 4
37 Analgesics, Opioid Phase 4,Phase 2
38 Narcotics Phase 4,Phase 2
39 Opiate Alkaloids Phase 4
40 Anti-Bacterial Agents Phase 4,Phase 3
41 Antibiotics, Antitubercular Phase 4,Phase 3
42 Anti-Infective Agents Phase 4,Phase 3,Phase 2
43 Antimetabolites Phase 4
44 Antitubercular Agents Phase 4,Phase 3
45 Renal Agents Phase 4
46 Autonomic Agents Phase 4,Phase 3,Not Applicable
47 Anticoagulants Phase 4,Phase 2
48 Antiparkinson Agents Phase 4,Phase 3
49 Calcium, Dietary Phase 4,Phase 2
50 Psychotropic Drugs Phase 4,Phase 3

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Clinical Efficacy of Changing the InterStim® Parameters in Patients With Interstitial Cystitis/Painful Bladder Syndrome Unknown status NCT01312259 Phase 4
2 Botulinum A Toxin in the Treatment of Patients With Painful Bladder Syndrome Unknown status NCT01157507 Phase 4 Intravesical injection of Botulinum A Toxin;Placebo
3 Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis Completed NCT01195116 Phase 4 Dexmedetomidine;Normal Saline
4 Intravesicular Onabotulinumtoxin A in Interstitial Cystitis Completed NCT02297100 Phase 4 Onabotulinumtoxin A
5 Intranasal Oxytocin for the Treatment of Pain Associated With Interstitial Cystitis Completed NCT00919802 Phase 4 Oxytocin
6 Intranasal Ketorolac Tromethamine (Sprix) for Acute Pain of Interstitial Cystitis Flare of Pain Completed NCT02000401 Phase 4 Ketorolac Tromethamine
7 Botox as a Treatment for Interstitial Cystitis in Women Completed NCT00194610 Phase 4 Botox
8 Reduction of Bladder Injection Pain With Belladonna Opiate Suppository Completed NCT02600715 Phase 4 Onabotulinumtoxin A (BoNT);belladonna;Morphine;Placebo;Active B&O suppository of belladonna
9 Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
10 Interstitial Cystitis: Examination of the Central Autonomic Network Recruiting NCT03008382 Phase 4 Metoprolol Tartrate Oral Tablet;Placebo Oral Tablet
11 Chronic Pain Risk Associated With Menstrual Period Pain Recruiting NCT02214550 Phase 4 microgestin 1/20
12 Effectiveness and Safety Study of Pentosan Polysulfate Sodium for the Treatment of Interstitial Cystitis Terminated NCT00086684 Phase 4 Pentosan polysulfate sodium 100 mg;Placebo;Pentosan polysulfate sodium 100 mg
13 Efficacy of Gralise® for Chronic Pelvic Pain Terminated NCT01678911 Phase 4 Gralise
14 Trial of Viagra' in Men With Chronic Pelvic Pain Syndrome Type III Terminated NCT00194597 Phase 4 Viagra (sildenafil citrate)
15 Acupuncture for the Treatment of Interstitial Cystitis (IC) Symptoms Unknown status NCT00094874 Phase 3
16 Efficacy Study of Adalimumab to Treat Interstitial Cystitis Completed NCT01295814 Phase 3 Adalimumab
17 Omalizumab in Interstitial Cystitis/Bladder Pain Syndrome Completed NCT01294878 Phase 3 omalizumab
18 URACYST® For the Treatment of GAG Deficient Interstitial Cystitis Completed NCT00150488 Phase 2, Phase 3
19 Efficacy of Amitriptyline for Painful Bladder Syndrome (PBS) Completed NCT00124306 Phase 3 Amitriptyline
20 Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis Completed NCT02497976 Phase 3 Placebo
21 A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression Completed NCT02497287 Phase 3 Esketamine (Intranasal Spray);Duloxetine (Oral Antidepressant);Escitalopram (Oral Antidepressant);Sertraline (Oral Antidepressant);Venlafaxine Extended Release (XR) (Oral Antidepressant)
22 A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis Recruiting NCT02787083 Phase 3 Mirabegron;Placebo
23 Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Active, not recruiting NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
24 Efficacy Study of Bladder Instillation and Gabapentin on Interstitial Cystitis/Bladder Pain Syndrome. Not yet recruiting NCT03463915 Phase 3 Gabapentin Oral Capsule [Neurontin];Placebo Oral Capsule [CEBOCAP]
25 A Randomized Multicenter Double-Blind CT to Evaluate the Efficacy and Safety of Mycophenolate Mofetil . . . Terminated NCT00451867 Phase 3 Mycophenolate Mofetil;Mycofenolate Mofetil (MMF);Placebo
26 Efficacy of Botulinum Toxin Type A in Patients With Bladder Pain Syndrome/Intersticial Cystitis and Hunners' Lesions Unknown status NCT01437579 Phase 2
27 Cyclosporine in Interstitial Cystitis: Efficacy, Safety and Mechanism of Action Completed NCT01990898 Phase 2 Cyclosporine
28 Prospective Trial Comparing Response to Hyperbaric Oxygen Treatment in Patients With Interstitial Cystitis Completed NCT01479725 Phase 2
29 Efficacy and Safety Study of Uracyst to Treat Interstitial Cystitis/Painful Bladder Syndrome Completed NCT00919113 Phase 2 2% sodium chondroitin sulfate;Placebo
30 Interstitial Cystitis Completed NCT00056251 Phase 2
31 An Effectiveness And Safety Study Of PD 0299685 For The Treatment Of Symptoms Associated With Interstitial Cystitis Completed NCT00739739 Phase 2 PD 0299685 at 15mg BID;PD 0299685 at 30mg BID;placebo for PD 0299685
32 Intravesical Botulinum Toxin A Injections in Treatment of Interstitial Cystitis Refractory to Conventional Treatment Completed NCT01969773 Phase 2 Botulinum toxin A;Normal saline instillation
33 Phase II Study Efficacy and Safety of Two Dosing Regimens of MN-001 in Patients With Interstitial Cystitis Completed NCT00295854 Phase 2 MN-001 BID;MN-001;Placebo
34 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome Completed NCT02411110 Phase 2
35 A Pilot Clinical Investigation of the Efficacy and Safety of Uracyst® Versus Placebo in Patients With Interstitial Cystitis/Painful Bladder Syndrome. Completed NCT00527917 Phase 2
36 An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis Completed NCT00601484 Phase 2 PF-04383119;Placebo
37 Intravesical Instillation of Liposome Encapsulated Botulinum Toxin A (Lipotoxin) in Treatment of Interstitial Cystitis Completed NCT02247557 Phase 2 Liposome encapsulated BoNT-A;BOTOX 200U in normal saline;Normal saline
38 Study of Biomarkers and the Relaxation Response Using Guided Imagery in Women With IC Completed NCT00420550 Phase 2
39 A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) Completed NCT01613586 Phase 2 ASP3652;Placebo
40 Efficacy and Safety of AQX-1125 in IC/BPS Completed NCT01882543 Phase 2 AQX-1125;Placebo
41 A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis With Hunner's Lesions Completed NCT02395042 Phase 2 LiRIS®;LiRIS Placebo
42 Phase I/II Randomized, Placebo-Controlled Study of Capsaicin for Interstitial Cystitis and Vulvar Vestibulitis Completed NCT00004316 Phase 1, Phase 2 capsaicin
43 Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients Completed NCT01997983 Phase 1, Phase 2
44 The Safety and Efficacy of Gefapixant (AF-219/MK-7264) in Female Subjects With Interstitial Cystitis /Bladder Pain Syndrome Completed NCT01569438 Phase 2 Gefapixant;Sugar Pill
45 Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis Completed NCT00517868 Phase 2 URG101;Placebo
46 OXN PR vs Placebo in Opioid-naive Subjects Suffering From Severe Pain Due to Bladder Pain Syndrome (BPS) Completed NCT01197261 Phase 2 Oxycodone naloxone prolonged release tablets;Placebo tablets
47 Study of U101 for Bladder Pain and/or Urgency Completed NCT00256542 Phase 2 Alkalinized Lidocaine-Heparin
48 A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression Completed NCT01998958 Phase 2 Esketamine 14 mg;Esketamine 28 mg;Esketamine 56 mg;Esketamine 84 mg;Placebo
49 A Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Recruiting NCT03282318 Phase 2 ASP6294;Placebo
50 Evaluation of Intravesical LP08 in Patients With Interstitial Cystitis/Painful Bladder Syndrome Recruiting NCT01393223 Phase 2 LP-08 80mg;Normal Saline Placebo;LP-08 20mg

Search NIH Clinical Center for Chronic Interstitial Cystitis

Genetic Tests for Chronic Interstitial Cystitis

Anatomical Context for Chronic Interstitial Cystitis

MalaCards organs/tissues related to Chronic Interstitial Cystitis:

41
Prostate, T Cells, Brain, Breast, Endothelial, Kidney, Liver

Publications for Chronic Interstitial Cystitis

Articles related to Chronic Interstitial Cystitis:

(show all 25)
# Title Authors Year
1
Pain: Novel lidocaine delivery device for chronic interstitial cystitis. ( 22890300 )
2012
2
Decreased viral load and symptoms of polyomavirus-associated chronic interstitial cystitis after intravesical cidofovir treatment. ( 19292661 )
2009
3
Intravesical botulinum toxin type A in chronic interstitial cystitis: results of a pilot study. ( 18080606 )
2007
4
Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. ( 16123573 )
2005
5
Lipofuscinosis of the urinary bladder: a complication of chronic interstitial cystitis. ( 12418480 )
2002
6
Chronic interstitial cystitis and systemic lupus erythematosus in an 8-year-old girl. ( 9543374 )
1998
7
Chronic interstitial cystitis occurring during the shift between rheumatoid arthritis and lupus. ( 8187433 )
1994
8
Traditional acupuncture and electrical stimulation of the posterior tibial nerve. A trial in chronic interstitial cystitis. ( 8493470 )
1993
9
Chronic interstitial cystitis. Successful treatment with intravesical idocaine. ( 1462157 )
1992
10
Association of chronic interstitial cystitis, protein-losing enteropathy and paralytic ileus with seronegative systemic lupus erythematosus: case report and review of the literature. ( 1606774 )
1992
11
The management of chronic interstitial cystitis by substitution cystoplasty. ( 2913346 )
1989
12
Chronic interstitial cystitis: a heterogeneous syndrome. ( 3795363 )
1987
13
Chronic interstitial cystitis and subcutaneous heparin. ( 2865477 )
1985
14
Conservative management of chronic interstitial cystitis: transcutaneous electrical nerve stimulation and transurethral resection. ( 3872946 )
1985
15
Chronic interstitial cystitis. ( 2862550 )
1985
16
Chronic interstitial cystitis. ( 2862324 )
1985
17
Chronic interstitial cystitis: increased levels of eosinophil cationic protein in serum and urine and an ameliorating effect of subcutaneous heparin. ( 6612233 )
1983
18
Chronic interstitial cystitis as an initial major manifestation of systemic lupus erythematosus. ( 6975827 )
1981
19
The surgical treatment of chronic interstitial cystitis. ( 875802 )
1977
20
Chronic interstitial cystitis. ( 5159574 )
1971
21
The management of chronic interstitial cystitis by differential sacral neurotomy. ( 5782386 )
1969
22
HUNNER'S ULCER (CHRONIC INTERSTITIAL CYSTITIS). A MANIFESTATION OF COLLAGEN DISEASE. ( 14346453 )
1965
23
The role of hyperemia in the treatment of chronic interstitial cystitis. ( 13783247 )
1961
24
Chronic interstitial cystitis. ( 13832744 )
1960
25
The clinical effect of pituitary adrenocorticotrophic hormone in three cases of severe chronic interstitial cystitis. ( 13062390 )
1953

Variations for Chronic Interstitial Cystitis

Expression for Chronic Interstitial Cystitis

LifeMap Discovery
Genes differentially expressed in tissues of Chronic Interstitial Cystitis patients vs. healthy controls: 35 (show top 50) (show all 462)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) Urinary System + 9.09 0.000
2 MUC15 mucin 15, cell surface associated Urinary System - 7.48 0.000
3 MMP3 matrix metallopeptidase 3 Urinary System + 7.26 0.000
4 CRISP3 cysteine-rich secretory protein 3 Urinary System - 7.12 0.000
5 FMO9P flavin containing monooxygenase 9 pseudogene Urinary System - 7.00 0.000
6 DHRS2 dehydrogenase/reductase (SDR family) member 2 Urinary System - 6.96 0.000
7 C10orf99 chromosome 10 open reading frame 99 Urinary System - 6.96 0.000
8 PCSK1 proprotein convertase subtilisin/kexin type 1 Urinary System + 6.87 0.000
9 CXCL8 chemokine (C-X-C motif) ligand 8 Urinary System + 6.50 0.000
10 SNX31 sorting nexin 31 Urinary System - 6.40 0.000
11 FUT9 fucosyltransferase 9 (alpha (1,3) fucosyltransferase) Urinary System - 6.36 0.000
12 UPK1A uroplakin 1A Urinary System - 6.34 0.000
13 UPK3A uroplakin 3A Urinary System - 6.32 0.000
14 VSTM2A V-set and transmembrane domain containing 2A Urinary System - 6.20 0.000
15 BTBD16 BTB (POZ) domain containing 16 Urinary System - 6.20 0.000
16 BHMT betaine--homocysteine S-methyltransferase Urinary System - 6.13 0.000
17 ELF5 E74-like factor 5 (ets domain transcription factor) Urinary System - 6.02 0.000
18 WIF1 WNT inhibitory factor 1 Urinary System - 6.00 0.000
19 CXCL13 chemokine (C-X-C motif) ligand 13 Urinary System + 5.99 0.000
20 CR2 complement component (3d/Epstein Barr virus) receptor 2 Urinary System + 5.76 0.000
21 HMGCS2 3-hydroxy-3-methylglutaryl-CoA synthase 2 (mitochondrial) Urinary System - 5.75 0.000
22 CRISP3 cysteine-rich secretory protein 3 Urinary System - 5.74 0.001
23 MMP1 matrix metallopeptidase 1 Urinary System + 5.74 0.000
24 RBP4 retinol binding protein 4, plasma Urinary System - 5.68 0.000
25 CCL18 chemokine (C-C motif) ligand 18 (pulmonary and activation-regulated) Urinary System + 5.65 0.000
26 IGL immunoglobulin lambda locus Urinary System + 5.64 0.002
27 CHI3L1 chitinase 3-like 1 (cartilage glycoprotein-39) Urinary System + 5.62 0.002
28 CHP2 calcineurin-like EF-hand protein 2 Urinary System - 5.60 0.000
29 CXCL13 chemokine (C-X-C motif) ligand 13 Urinary System + 5.60 0.001
30 UPK1B uroplakin 1B Urinary System - 5.59 0.001
31 TFPI2 tissue factor pathway inhibitor 2 Urinary System + 5.58 0.000
32 IL11 interleukin 11 Urinary System + 5.57 0.001
33 FGFR3 fibroblast growth factor receptor 3 Urinary System - 5.57 0.000
34 SOSTDC1 sclerostin domain containing 1 Urinary System - 5.55 0.000
35 FAM3B family with sequence similarity 3, member B Urinary System - 5.53 0.000
36 TMPRSS11E transmembrane protease, serine 11E Urinary System - 5.42 0.000
37 CWH43 cell wall biogenesis 43 C-terminal homolog Urinary System - 5.40 0.000
38 HLA-DQA1 major histocompatibility complex, class II, DQ alpha 1 Urinary System + 5.40 0.030
39 LTF lactotransferrin Urinary System + 5.39 0.000
40 LTF lactotransferrin Urinary System + 5.36 0.000
41 TDO2 tryptophan 2,3-dioxygenase Urinary System + 5.35 0.000
42 SLC14A1 solute carrier family 14 (urea transporter), member 1 (Kidd blood group) Urinary System - 5.30 0.000
43 GREM1 gremlin 1, DAN family BMP antagonist Urinary System + 5.30 0.000
44 IGLV3-19 immunoglobulin lambda variable 3-19 Urinary System + 5.29 0.000
45 MMP12 matrix metallopeptidase 12 Urinary System + 5.27 0.000
46 SULT2A1 sulfotransferase family, cytosolic, 2A, dehydroepiandrosterone (DHEA)-preferring, member 1 Urinary System - 5.26 0.000
47 CHRDL2 chordin-like 2 Urinary System + 5.26 0.000
48 PRAC1 prostate cancer susceptibility candidate 1 Urinary System - 5.24 0.000
49 GOLT1A golgi transport 1A Urinary System - 5.22 0.000
50 IGLJ3 immunoglobulin lambda joining 3 Urinary System + 5.16 0.000
Search GEO for disease gene expression data for Chronic Interstitial Cystitis.

Pathways for Chronic Interstitial Cystitis

Pathways related to Chronic Interstitial Cystitis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.19 CD40LG CD79A

GO Terms for Chronic Interstitial Cystitis

Biological processes related to Chronic Interstitial Cystitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 B cell differentiation GO:0030183 8.96 CD40LG CD79A
2 B cell proliferation GO:0042100 8.62 CD40LG CD79A

Sources for Chronic Interstitial Cystitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....